Cargando…
Pan-Cancer Analysis Reveals That E1A Binding Protein p300 Mutations Increase Genome Instability and Antitumor Immunity
E1A binding protein p300 (EP300) is mutated in diverse cancers. Nevertheless, a systematic investigation into the associations of EP300 mutations with genome instability and antitumor immunity in pan-cancer remains lacking. Using the datasets from The Cancer Genome Atlas, we analyzed the correlation...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488206/ https://www.ncbi.nlm.nih.gov/pubmed/34616736 http://dx.doi.org/10.3389/fcell.2021.729927 |
_version_ | 1784578111051923456 |
---|---|
author | Chen, Zuobing Chen, Canping Li, Lin Zhang, Tianfang Wang, Xiaosheng |
author_facet | Chen, Zuobing Chen, Canping Li, Lin Zhang, Tianfang Wang, Xiaosheng |
author_sort | Chen, Zuobing |
collection | PubMed |
description | E1A binding protein p300 (EP300) is mutated in diverse cancers. Nevertheless, a systematic investigation into the associations of EP300 mutations with genome instability and antitumor immunity in pan-cancer remains lacking. Using the datasets from The Cancer Genome Atlas, we analyzed the correlations between EP300 mutations and genome instability and antitumor immune response in 11 cancer types. Compared to EP300-wild-type cancers, EP300-mutated cancers had significantly higher tumor mutation burden (TMB) in 10 cancer types. EP300-mutated cancers harbored a much higher fraction of microsatellite instable cancers in the colon and gastric cancers. EP300 was co-mutated with genes involved in DNA damage repair pathways in multiple cancers. Furthermore, compared to EP300-wild-type cancers, EP300-mutated cancers had significantly higher immune cytolytic activity scores and ratios of immune-stimulatory over immune-inhibitory signatures in diverse cancers. Also, EP300-mutated cancers showed significantly higher programmed death-ligand 1 (PD-L1) expression levels than EP300-wild-type cancers. The increased TMB, antitumor immune activity, and PD-L1 expression indicated a favorable response to immune checkpoint inhibitors (ICIs) in EP300-mutated cancers, as evident in three cancer cohorts treated with ICIs. Thus, the EP300 mutation could be a predictive biomarker for the response to immunotherapy. |
format | Online Article Text |
id | pubmed-8488206 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84882062021-10-05 Pan-Cancer Analysis Reveals That E1A Binding Protein p300 Mutations Increase Genome Instability and Antitumor Immunity Chen, Zuobing Chen, Canping Li, Lin Zhang, Tianfang Wang, Xiaosheng Front Cell Dev Biol Cell and Developmental Biology E1A binding protein p300 (EP300) is mutated in diverse cancers. Nevertheless, a systematic investigation into the associations of EP300 mutations with genome instability and antitumor immunity in pan-cancer remains lacking. Using the datasets from The Cancer Genome Atlas, we analyzed the correlations between EP300 mutations and genome instability and antitumor immune response in 11 cancer types. Compared to EP300-wild-type cancers, EP300-mutated cancers had significantly higher tumor mutation burden (TMB) in 10 cancer types. EP300-mutated cancers harbored a much higher fraction of microsatellite instable cancers in the colon and gastric cancers. EP300 was co-mutated with genes involved in DNA damage repair pathways in multiple cancers. Furthermore, compared to EP300-wild-type cancers, EP300-mutated cancers had significantly higher immune cytolytic activity scores and ratios of immune-stimulatory over immune-inhibitory signatures in diverse cancers. Also, EP300-mutated cancers showed significantly higher programmed death-ligand 1 (PD-L1) expression levels than EP300-wild-type cancers. The increased TMB, antitumor immune activity, and PD-L1 expression indicated a favorable response to immune checkpoint inhibitors (ICIs) in EP300-mutated cancers, as evident in three cancer cohorts treated with ICIs. Thus, the EP300 mutation could be a predictive biomarker for the response to immunotherapy. Frontiers Media S.A. 2021-09-20 /pmc/articles/PMC8488206/ /pubmed/34616736 http://dx.doi.org/10.3389/fcell.2021.729927 Text en Copyright © 2021 Chen, Chen, Li, Zhang and Wang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Chen, Zuobing Chen, Canping Li, Lin Zhang, Tianfang Wang, Xiaosheng Pan-Cancer Analysis Reveals That E1A Binding Protein p300 Mutations Increase Genome Instability and Antitumor Immunity |
title | Pan-Cancer Analysis Reveals That E1A Binding Protein p300 Mutations Increase Genome Instability and Antitumor Immunity |
title_full | Pan-Cancer Analysis Reveals That E1A Binding Protein p300 Mutations Increase Genome Instability and Antitumor Immunity |
title_fullStr | Pan-Cancer Analysis Reveals That E1A Binding Protein p300 Mutations Increase Genome Instability and Antitumor Immunity |
title_full_unstemmed | Pan-Cancer Analysis Reveals That E1A Binding Protein p300 Mutations Increase Genome Instability and Antitumor Immunity |
title_short | Pan-Cancer Analysis Reveals That E1A Binding Protein p300 Mutations Increase Genome Instability and Antitumor Immunity |
title_sort | pan-cancer analysis reveals that e1a binding protein p300 mutations increase genome instability and antitumor immunity |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488206/ https://www.ncbi.nlm.nih.gov/pubmed/34616736 http://dx.doi.org/10.3389/fcell.2021.729927 |
work_keys_str_mv | AT chenzuobing pancanceranalysisrevealsthate1abindingproteinp300mutationsincreasegenomeinstabilityandantitumorimmunity AT chencanping pancanceranalysisrevealsthate1abindingproteinp300mutationsincreasegenomeinstabilityandantitumorimmunity AT lilin pancanceranalysisrevealsthate1abindingproteinp300mutationsincreasegenomeinstabilityandantitumorimmunity AT zhangtianfang pancanceranalysisrevealsthate1abindingproteinp300mutationsincreasegenomeinstabilityandantitumorimmunity AT wangxiaosheng pancanceranalysisrevealsthate1abindingproteinp300mutationsincreasegenomeinstabilityandantitumorimmunity |